RhoVac is a pharmaceutical company. Today, the focus is on the development of vaccines for the treatment of metastatic cancer. Immunotherapy treatment is a significant part of the operations where the body's immune system is used to fight and eliminate cancer cell. The company's drug candidate is used in combination with surgery or radiation therapy. The company was established in 2007 and is based in Lund.
CEO
Chairman Of The Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| RQ Solutions ApS | 14,07 | 14,07 | 2019-06-30 |
| Ventac Holding (Cyprus) Ltd | 12,49 | 12,49 | 2019-06-30 |
| Avanza Pension | 6,22 | 6,22 | 2019-06-30 |
| Nordic Cross Asset Management | 5,89 | 5,89 | 2019-07-31 |
| Nordnet Pensionsförsäkring | 3,59 | 3,59 | 2019-06-30 |
| Nils Berntsson | 2,13 | 2,13 | 2019-06-30 |
| John Bäck | 1,55 | 1,55 | 2019-06-30 |
| Ola Forsman | 1,41 | 1,41 | 2019-06-30 |
| Anders Bremer | 1,31 | 1,31 | 2019-06-30 |
| Björn Tommy Atterling | 1,05 | 1,05 | 2019-06-30 |
2019-08-30 Delårsrapport 2019-Q2
2019-11-15 Delårsrapport 2019-Q3
2020-02-11 Bokslutskommuniké 2019